Results 321 to 330 of about 251,409 (391)

N‐1 semi‐continuous transient perfusion in shake flask for ultra‐high density seeding of CHO cell cultures in benchtop bioreactors

Biotechnology Progress, EarlyView.
Abstract One strategy to enhance the production of biological therapeutics is using transient perfusion in the preculture (N‐1 stage) to seed the production culture (N stage) at ultra‐high cell densities (>10 x 106 viable cells/mL). This very high seeding density improves cell culture performance by shortening the timeline and/or achieving higher final
Lucas Lemire, Sebastian‐Juan Reyes, Yves Durocher, Robert Voyer, Olivier Henry, Phuong Lan Pham   +5 more
wiley   +1 more source

An open‐label, single‐arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR‐positive, HER2‐negative advanced breast cancer patients: BRIGHT‐1 trial

Cancer Communications, EarlyView.
Abstract Background Bireociclib (XZP‐3287) is a novel selective cyclin‐dependent kinase 4 and 6 (CDK4/6) inhibitor, with a favorable safety profile demonstrated in preclinical and phase I studies. BRIGHT‐1 aimed to further explore the efficacy and safety of bireociclib monotherapy in patients with locally advanced, recurrent or metastatic, hormone ...
Jiayu Wang, Qingyuan Zhang, Tao Sun, Huiping Li, Ying Cheng, Zhongsheng Tong, Huihui Li, Wei Li, Jingfen Wang, Yuee Teng, Xinhong Wu, Jing Cheng, Zhendong Chen, Zhengqiu Zhu, Li Wang, Mingming Liu, Xianghui Duan, Lingmei Xu, Binghe Xu   +18 more
wiley   +1 more source

Through the Haze of Hemorrhage: Unraveling Leptospirosis With Diffuse Alveolar Hemorrhage. [PDF]

Cureus
Vasireddy M, Logithasan N, Senthil N, Chenguttuvan A, Gandikota P.   +4 more
europepmc   +1 more source

A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort

Cancer Communications, EarlyView.
Abstract Background The combined use of anti‐programmed cell death protein 1 (PD‐1)/anti‐cytotoxic T‐lymphocyte associated protein 4 (CTLA‐4) checkpoint inhibitors has been effective in various cancer types. The Southwest Oncology Group (SWOG) Dual Anti‐CTLA‐4 and Anti‐PD‐1 Blockade in Rare Tumors (DART) S1609 study investigated ipilimumab and ...
Young Kwang Chae, Megan Othus, Sandip Pravin Patel, Raid Aljumaily, Khine Z. Win, Tanya Pejovic, Sajeve S. Thomas, William R. Robinson III, Hye Sung Kim, Liam Il‐Young Chung, Christine M. McLeod, Helen X. Chen, Elad Sharon, Howard Streicher, Christopher W. Ryan, Charles D. Blanke, Razelle Kurzrock   +16 more
wiley   +1 more source

Circulating CCN6/WISP3 in type 2 diabetes mellitus patients and its correlation with insulin resistance and inflammation: statistical and machine learning analyses. [PDF]

BMC Med Inform Decis Mak
Afrisham R, Jadidi Y, Moradi N, Ayyoubzadeh SM, Fadaei R, Kiani Ghalesardi O, Farrokhi V, Alizadeh S.   +7 more
europepmc   +1 more source

Physiologic requirements for auxiliary liver homotransplantation [PDF]

, 1965
Dickinson, TC, Faris, TD, Marchioro, TL, Porter, KA, Starzl, TE   +4 more
core   +1 more source

Diagnosis of Perforated Appendiceal Diverticulitis Following Laparoscopic Appendectomy. [PDF]

Cureus
Sousa P, Magalhães E, Marques M, Cracel Lourenço J, Costa Pereira JM.   +4 more
europepmc   +1 more source

First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial

Cancer Communications, EarlyView.
Abstract Background The ASTRUM‐005 study previously demonstrated a significant overall survival (OS) benefit with serplulimab (a programmed death 1 inhibitor) plus chemotherapy versus chemotherapy alone in previously untreated extensive‐stage small‐cell lung cancer (ES‐SCLC).
Ying Cheng, Shuang Zhang, Liang Han, Lin Wu, Jun Chen, Peiyan Zhao, Hongmei Sun, Guilan Wen, Yinghua Ji, Anastasia Zimina, Jianhua Shi, Zhijie Pan, Jinsheng Shi, Xicheng Wang, Yuansong Bai, Tamar Melkadze, Yueyin Pan, Xuhong Min, Maksym Viguro, Xingya Li, Yanqiu Zhao, Junquan Yang, Tamta Makharadze, Ekaterine Arkania, Haoyu Yu, Jing Li, Fang Yang, Xinyi Yang, Chen Ling, Qingyu Wang, Yongqiang Shan, Jun Zhu, the ASTRUM‐005 Study Group   +32 more
wiley   +1 more source